Different gene expression of MDM2, GAGE-1, –2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia

T Schlott¹, K Ahrens¹, I Ruschenburg¹, S Reimer¹, H Hartmann² and M Droese¹

¹Department of Cytopathology, ²Division of Gastroenterology and Endocrinology, Georg-August-University, Robert-Koch-str. 40, 37075 Goettingen, Germany

Summary Overexpression and/or mutations of oncogenes, tumour suppressor genes and tumour rejection genes have been observed in several human malignancies. Their analyses might be of diagnostic importance. Therefore, malignant hepatocytes derived from hepatocellular carcinoma (HCC) tissue as well as non-malignant hepatocytes derived from focal nodular hyperplasia (FNH) were studied. Samples containing normal human hepatocytes (HC) served as controls. Cellular material was obtained by fine-needle aspiration biopsy guided by ultrasound. Cells were analysed for expression and mutation of the oncogene MDM2, the genes GAGE-1, -2 coding for tumour-associated antigens and the candidate tumour suppressor gene FHIT. Different patterns of non-mutant FHIT transcripts including precise deletion of exons were found in 7/10 HCC, 2/10 FNH and 2/10 HC. However, expression of non-mutant GAGE-1, -2 RNA was demonstrated exclusively in 6/10 HCC samples. Further genetic features specific of HCC were point mutations in a zinc-finger motif of MDM2 (3/10 HCC samples). Neither GAGE-1, -2 expression nor MDM2 mutations were observed in the FNH samples, or in normal hepatocytes. Our findings suggest that occurrence of variable FHIT transcripts is not restricted to hepatic malignant tumours. In contrast, MDM2 mutations and GAGE-1, -2 expression were associated with HCC specimens. Therefore, the RT-PCR assays for GAGE-1, -2 and MDM2 might be useful adjuncts in cytodiagnosis of liver neoplasms.

Keywords: fine-needle aspiration biopsy; hepatocellular carcinoma; focal nodular hyperplasia; MDM2; GAGE-1, GAGE-2, FHIT

The oncogene MDM2 located on chromosome 12 is amplified in solid tumours (Fakhraizadeh et al, 1991; Oliner et al, 1992). Overexpression of the gene is an important tumorigenic mechanism immortalizing rat fibroblasts (Finlay, 1993) and is associated with tumour progression in leukaemias (Bueso-Ramos et al, 1993). MDM2 encodes a phosphoprotein with multiple functions. The N-terminus of MDM2 protein forms a complex with the central tumour suppressor p53, thus blocking the trans-activating functions of p53 (Momand et al, 1992). The central acidic domain of MDM2 interacts with the TATA-binding protein TBP (Leveillard and Wasylyk, 1997). The C-terminus of MDM2 contains three zinc-finger motifs, two of them forming a RING finger structure (Boddy et al, 1994) which binds the basal transcription factor TAFII250 (Leveillard and Wasylyk, 1997). These findings suggest an important role of MDM2 protein in regulation of cell division and transcriptional control.

So far, only a few publications are available on the GAGE-1 and GAGE-2 genes. Both genes are members of a family of closely related genes coding for the MAGE-GAGE and BAGE-antigens presented by MHC class I molecules (Van der Bruggen et al, 1991; Gaugler et al, 1994; Böel et al, 1995). The GAGE-1 and GAGE-2 tumour-associated antigens are recognized by autologous cytolytic T lymphocytes (Van den Eynde et al, 1995) and are expressed in tumour entities such as ovarian, colorectal and lung carcinomas (Van den Eynde et al, 1995; Russo et al, 1996). The GAGE-1 and GAGE-2 antigens are also testis antigens because of their absence in normal tissue except for testis (Van den Eynde et al, 1995). Therefore, they are proposed as diagnostic markers.

The gene FHIT, a new member of the human histidine triad gene family, has been isolated recently (Ohta et al, 1996). This gene is located on the short arm of chromosome 3 in a region carrying multiple tumour suppressor genes presumably involved in cancer development (LaForgia et al, 1991; Kastury et al, 1996). Genetic studies have defined this locus as unstable. FHIT contains fragile sites, one of which represents the t(3;8) breakpoint observed in familial renal cell carcinoma (Cohen et al, 1979; Wang and Perkins, 1984), while the other one, designated FRA3B, was originally described as one of the most fragile sites of the human genome (LeBeau and Rowley, 1984). FHIT is subjected to genetic alterations such as homozygous deletions or splicing abnormalities. Many samples obtained from malignant tumours of the oesophagus, stomach, colon, cervix, breast, and head and neck revealed aberrant FHIT transcripts containing exon deletions and insertions (Negrini et al, 1996; Sozzi et al, 1996; Thigalingam et al, 1996; Virgilio et al, 1996; Gemma et al, 1997; Hendricks et al, 1997). Furthermore, in small cell lung carcinomas and non-small cell lung cancers, microsatellite polymorphism analyses, loss of hybridization (LOH) analyses and hybridization experiments revealed characteristic alterations within FHIT (Fong et al, 1997; Sozzi et al, 1996, 1997) supposed to represent initial events of lung cancer development (Sozzi et al, 1997).
The aim of the present study was to search for genetic alterations that might serve as markers in cytologically based diagnosis of malignant hepatic tumours. The data published so far regarding MDM2, GAGE-1, -2 and FHIT suggest that analysis of the latter might contribute to the differentiation of malignant hepatocytes [i.e. derived from hepatocellular carcinoma (HCC)] from benign proliferating hepatocytes [i.e. focal nodular hyperplasia (FNH)] and normal hepatocytes respectively. Therefore, a combined expression assay for FHIT, GAGE-1, -2, and MDM2 in cells obtained by fine-needle aspiration was used and these genetic data were correlated with clinicopathological features.

**MATERIALS AND METHODS**

**Sample collection**

Slides examined were obtained by ultrasound-guided fine-needle aspiration from ten patients with HCC (five women, five men) and ten patients with FNH (eight women, two men). In all cases, cytodiagnosis was subsequently confirmed by histological and/or clinical findings. The slides were routinely stained according to May–Grünwald–Giemsa and stored up to 3 years. Additionally, ten controls (hepatocyte cultures, fetal hepatocytes, specimens from liver autopsy) were analysed. Two cell lines isolated from fresh HCC samples described in the previous study of Schlott et al (1997) were used for establishing the tests.

**RNA isolation and cDNA amplification**

Glass slide smears were kept in xylene for 2 days to remove cover slips. The cells were scraped into sterile Eppendorf microfuge tubes with razor-blades and washed once with xylene and twice with ethanol (96%, v/v) to remove any traces of xylene. Cells and cellular debris were harvested by centrifugation (500 rpm at 4°C) and dried in a speed vacuum concentrator (Eppendorf, Hamburg, Germany). RNA was isolated from malignant and non-malignant hepatocytes with the RNeasy Total RNA Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. RNA was eluted from the affinity columns and concentrated in a final volume of 5 µl water by vacuum centrifugation. To inhibit degrada
tion of RNA, plastic ware and solutions were treated with 0.1% (w/v) DEPC (Sigma, Munich, Germany). Oligonucleotide primers previously used for amplification of a nucleotide sequence shared by GAGE-1 and GAGE-2 RNA. These primers give a 244 bp product. All PCR procedures were performed as described (Van den Eynde et al, 1995).

Primers used for amplification of FHIT sequences were 5' - CACTGGAAAGTGAAGAGCT-3' (exon 3, sense primer 1, position −201 to −223), 5'- TCCGTAGTCGTATCATCACC-3' (exon 3, sense primer 2, position −142 to −162), and 5'- CACCTCT- GATCTCAAAGGCC-3' (exon 9, antisense primer, position 379 to 398). The sequencing were selected from published data of Ohta et al (1996). The combination sense primer 1/antisense primer yielded a 599 bp fragment, combination sense primer 2/antisense primer a 561 bp fragment. Following an initial denaturing step at 95°C for 7 min, cDNA was amplified 40 times in three temperature cycles. In each amplification series a 30-s melting cycle at 95°C was followed by a combined annealing cycle for 1 min at 60°C, and an extension cycle for 2 min at 72°C. The final round was completed with a primer extension for 240 s at 72°C. Cycling conditions of the second round PCR differed from the first one in annealing temperature (62°C) and temperature cycle number (30 cycles).

**Gel electrophoresis and cDNA sequencing**

For visualization, 5 µl of each PCR assay (final volume 100 µl) was separated on a 3% (w/v) agarose gel containing 0.5 µg ethidium bromide per ml. The gel was registered by means of a CCD camera (Biometra, Goettingen, Germany). FHIT-PCR products were separated on 3% low-melting agarose (Biozym, Hameln, Germany) and cut from the gel. The QIAEX II Gel Extraction Kit (QIAGEN, Hilden, Germany) was used to purify the FHIT cDNA. The GAGE-1, -2 and MDM2 amplification products were purified with the QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany).

A total of 200 ng of isolated DNA were labelled with the PRISM Ready Dye Deoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Weiterstadt, Germany) according to the manufacturer’s instructions and analysed in an Applied Biosystems DNA sequencer (model 377). Oligonucleotides previously used for amplification of fragments served as sequencing primers.

**RESULTS**

In this study, HCC cell lines formerly described by Schlott et al (1997) were used for establishing and optimizing three RT-PCR assays based on the detection of MDM2, GAGE-1, -2, and FHIT expression. These tests were ultimately applied on liver tissue and liver cells obtained by fine-needle aspiration.
MDM2 RNA was detected in all aspirates investigated. Figure 1 is representative for all samples investigated (HCC, FNH, HC). The PCR fragments obtained from the HCC, FNH and HC samples were analysed by automatic sequencing and sequence alignment. MDM2 point mutations were found exclusively in the MDM2 transcripts amplified from 3/10 HCC samples (Figure 2). The MDM2 mutations were located in a zinc-finger domain of MDM2 and could be divided into two groups. Evidence is given for a MDM2 mutation that has not been described so far. The genetic alteration was classified as a mis-sense mutation replacing the codon CGT by codon AGT. In consequence, the amino acid residue arginine in mature MDM2 might be converted into serine. The other two mutations have been described before and represent a frame-shift mutation inducing a premature stop codon (Schlott et al, 1997).

Expression of the GAGE-1, -2 genes was found in specimens from six patients with HCC (Figure 3). The PCR fragments did not show any gene mutations or deletions according to the data of automatic sequencing. The other samples (four HCC, ten FNH, ten normal liver specimens) did not contain GAGE-1, -2 RNA.

Aberrant transcripts were detected by amplifying FHIT RNA in seven HCC, two FNH and two HC specimens. Transcript sizes observed in agarose gel ranged from 190 bp to 561 bp (Figure 4). Because of the enhanced sensitivity of the semi-nested assay even low abundance transcripts were detected in the specimens. Five samples (three HCC, two FNH) did not reveal DNA signals corresponding to full length FHIT RNA (Figure 4, HCC sample 2). The FHIT expression patterns of two HCCs additionally revealed weak DNA bands larger than the expected size of 561 bp representing heteroduplexes formed between FHIT-splicing variants.

The nucleotide sequence of the full length FHIT cDNA, or the various transcripts found in the samples, was determined by automatic sequencing. None of the FHIT mRNAs showed point mutations or nucleotide insertions. In detail, the analysis revealed transcripts lacking exon 5–8, 4–6, 5–7, 5–6, 4–5, and 8 as described in former publications (Negrini et al, 1996; Sozzi et al, 1996; Thiagalingam et al, 1996; Virgilio et al, 1996; Gemma et al, 1997; Hendricks et al, 1997). Most of these transcript types were found in HCC and FNH entities under investigation and negative controls. However, the FHIT transcripts lacking exon 5–7 (264 bp) and exon 5–8 (193 bp) occurred in HCC and FNH, samples but not in normal hepatocytes. The nucleotide sequence of both mRNAs is shown in Figure 5. Analysis currently in progress has not yet detected these FHIT RNA types in non-neoplastic hepatocytes so far.
An overview on the expression pattern of HCC aspirates is demonstrated in Table 1.

**DISCUSSION**

From a clinical point of view, fine-needle aspiration biopsy is an important adjunct for diagnosing benign and malignant lesions of the liver. The cytodiagnostic criteria used for HCC are increased nucleocytoplasmic (N/C) ratio, trabecular pattern, atypical naked nuclei, bile production by malignant hepatocytes, multinucleated tumour cells and absence of bile duct epithelium (Ducatman, 1992). However, morphological changes associated with inflammatory and proliferative processes of the liver may often mimic malignancy in fine-needle aspirates. In particular, the differentiation between well-differentiated HCC and benign reactive conditions (i.e. FNH) can be very difficult in cytodiagnosis (Huebscher and Young, 1993).

In search for genetic markers associated with malignant liver neoplasms, benign and malignant cells of human liver were evaluated for genetic alterations concerning the oncogene MDM2, the GAGE-1, -2 genes, and the candidate tumour suppressor gene *FHIT* in the present study. Accordingly, sensitive nested RT-PCR and automatic laser scanning system were combined to characterize the expression and mutation of the target genes. Of note, other genetic techniques formerly used for this purpose, e.g. Southern blot hybridization and LOH analysis were not taken into consideration since they are difficult to perform on cytological specimens containing heterogeneous cell populations.

The MDM2 gene of many solid tumours reveals characteristic genetic alterations; among these, the most frequently recognized is gene amplification which is referred to as a major factor of MDM2 overexpression and an indicator of malignancy. Concerning liver neoplasms, amplification of the MDM2 should be a rare event since studies on hepatoblastoma cells showed non-amplified MDM2 genes in all samples analysed (Ohnishi et al, 1996). However, different alterations of MDM2 were detected recently in two HCC cell lines and further tumour entities, e.g. point mutations in a putative zinc-finger motif of MDM2 (Schlott et al, 1997).

In the present work, the respective assays were transferred to a larger pool of aspirates containing malignant or benign liver cells. Expression of the MDM2 gene was detected in all HCC, FNH and HC samples investigated. Interestingly, MDM2 point mutation was observed in HCC sample leading to conversion from Arg to Ser or to the loss of the three zinc-finger motifs. The functional consequences of the amino acid substitution located adjacent to zinc-finger motif 1 are speculative since NMR and crytallographical analysis on this phylogenetically conserved domain is lacking. However, the effects of the T-insertion, which was formerly discussed here in view of current publications. Accordingly, it has been shown recently for MDM2 protein that the C-terminal RING domain is involved in the repression of the cyclin-A gene which controls the transition from G1 to S phase. When transfecting cells with MDM2 RNA whose zinc-finger domain was deleted, high levels of cyclin-A (Leveillard and Wasylyk, 1997) often observed in MDM2 transformed cells, were noted. Moreover, MDM2 transcripts lacking the complete 3’-end with the three zinc-finger motifs naturally occur in tumour cells. These transcripts are able to transform cultivated mouse fibroblasts (Sigalas et al, 1996). Thus, it might be speculated that MDM2 frame-shift mutations detected...
in HCC are associated with synthesis of truncated MDM2 proteins contributing to malignancy. In vitro transfection assays on mouse hepatocytes might help to prove this hypothesis.

Expression of one of the proteins belonging to the family of tumour-associated antigens, i.e. MAGE-1, has already been reported for HCC (Yamashita et al, 1996); however, neoplasms of the liver have apparently not yet been analysed for the expression of the GAGE-1, -2 genes. In the present study, GAGE-1, -2 RNA was detected in 60% of HCC specimens, although some of the fine-needle aspirates have been stored for years. Interestingly, the data of Yamashita and co-workers (1996) revealed a comparable high percentage of MAGE-1 expression (75%) in fresh HCC samples derived from HCC cell lines and biopsies, respectively. The results of both studies favour the application of RNA-PCR assays on various kinds of material.

It is noteworthy that MDM2 mutations were only found in HCC cells showing absence of the GAGE-1, -2 expression. It suggests that synthesis of intact MDM2 proteins in HCC is associated with up-regulation of GAGE-1, -2 genes. However, this fact should be confirmed by further in vitro experiments on cultivated HCC cells in order to prove any physiological connection between both markers.

FHIT was selected for analysis, since former data indicated that aberrant FHIT transcripts may be potential indicators of malignancy. The present data indicate expression of aberrant FHIT transcripts in malignant as well as in non-malignant liver cells of archival fine-needle aspirates. This phenomenon is possibly due to the applying of semi-nested-PCR technique which favoured amplification of FHIT transcripts produced in small amounts. While this work was in progress, Chen et al (1998), also detected aberrant FHIT transcripts in fresh non-tumorous liver tissue. Similar results were obtained by other groups in premalignant and malignant lesions of bronchi, liver and brain (Fong et al., 1997; Panagopoulos et al., 1997). Taken together, these observations from different groups working independently still leave the question open whether it is possible to relate the detection of FHIT-splicing variants to malignant transformation.

Concerning liver cells, our data are not conclusive whether a characteristic FHIT expression pattern exists which might help to differentiate between non-neoplastic and neoplastic liver cells. This is due to the fact that two types of FHIT transcript lacking exons 5–7 and exons 5–8 were detected in HCC and FNH, but not in the negative controls. Thus, it can be argued that both transcripts might play a role in proliferation of malignant and non-malignant liver cells, but further experiments on a larger collection of hepatic samples are necessary to support this hypothesis. Interestingly, Fong and co-workers recently detected the transcript lacking exons 5–8 in Epstein–Barr virus-infected cell line and supposed it to be the result of transformation (Fong et al., 1997).

Other typical genetic alterations were not detectable in malignant and non-malignant liver cell FHIT RNA. Mutations, for example, which would be reliable indicators for inactivation of the putative FHIT tumour suppressor, could not be detected in either the histidine triad motif His-Xaa-His-Xaa-His of exon 8, a highly conserved region possibly involved in binding of zinc ions (Lima et al., 1996), or in other regions of FHIT amplification products. These results are in accordance with the data of Sozzi et al (1996) and Ohta et al (1996), who found FHIT mutations in coding regions to be rare events.

In summary, the FHIT assay did not allow differentiation between malignant hepatocytes, benign proliferating hepatocytes and normal hepatocytes tested in this study. Since formation of aberrant FHIT RNA appears to be a common feature of benign, non-neoplastic hepatocytes, the role of FHIT transcripts in hepatocellular transformation is elusive. In contrast, MDM2 mutations and GAGE-1, -2 expression were only present in HCC. Therefore, it might be of value to investigate whether the two assays can be used in routine cytodiagnostics of liver lesions.

Taking all demonstrated facts together, one can conclude that combining the GAGE-1, -2 PCR assay with other PCR assays based on the detection of other tumour rejection antigens, such as MAGE-1 and MAGE-3, may further optimize genetic detection of HCC in cytological material. Studies are currently under progress to test this hypothesis.

REFERENCES

Albitar M, Peschle C and Liebhaber SA (1989) Theta, zeta and epsilon globin messenger RNAs are expressed in adults. Blood 2: 629–637

Boddy MN, Freemont PS and Borden KLB (1994) The 53-associated protein MDM2 contains a newly characterized zinc-finger domain called the RING finger. Trends Biochem Sci 19: 188–189

Boel P, Wildmann C, Sensi ML, Brassieur R, Renaud JC, Coulié P, Boon T and Van der Bruggen P (1995) BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T-lymphocytes. Immunity 2: 167–175

Bueso-Ramos CE, Yang Y, DeLeon E, McCown P, Stass SA and Albitar M (1993) The human MDM2-oncogene is overexpressed in leukemias. Blood 82: 2617–2623

Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC and Brown RS (1979) Hereditary renal cell carcinoma associated with a chromosomal translocation. N Engl J Med 301: 592–595

Chen YJ, Chen PH and Chang JG (1998) Aberrant FHIT transcripts in hepatocellular carcinomas. Br J Cancer 77: 417–420

Ducatman BS (1992) Fine needle aspiration of the liver and pancreas. In Atlas of Diagnostic Cytopathology, Mitchell J (ed), pp. 319–320. WB Saunders: Philadelphia

Fakharzadeh SS, Trusko SP and George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in mouse tumor cell line. EMBO J 10: 1563–1569

Finlay CA (1993) The MDM2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301–306

Fong KM, Bieserstved EL, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassoool FV, Zimmermann PV, Giaccone G, Gazdar AF and Minna JD (1997) FHIT and FRASB 3p14.2 allele loss are common in lung cancer and pre-neoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 57: 2256–2267

Gayler B, Van den Eynde B, Van der Bruggen P, Romero P, Gaforio JJ, DePlaen E, Lethe B, Brassieur F and Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179: 921–930

Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP and Harris CC (1997) FHIT mutations in human primary gastric cancer. Cancer Res 57: 1435–1437

Hendricks DT, Taylor R, Reed M and Birrer J (1997) FHIT gene expression in human ovarian, endometrial and cervical cancer cell lines. Cancer Res 57: 2112–2115

Huebser SG and Young JA (1993) Liver. In Fine Needle Aspiration Cytology, Young JA (ed), pp. 141–142. Blackwell Scientific Publications: Oxford

Kastury K, Baflia R, Druck T, Ohta M, Cotticelli MG, Inoue H, Negrini M, Rugge M, Huang D, Croce CM, Palazzo J and Huebner K (1996) Potential gastrointestinal tumour suppressor locus at the 3p14.2 FRA3B site identified by homoygous deletions in tumor cell lines. Cancer Res 56: 978–983

LaForgia S, Morse B, Levy J, Barnea G, Cannizzaro LA, Li F, Nowell PC, LaForgia S, Morse B, Levy J, Barnea G, Cannizzaro LA, Li F, Nowell PC, Böel P, Wildmann C, Sensi ML, Brassieur R, Renaud JC, Coulié P, Boon T and Van der Bruggen P (1995) BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T-lymphocytes. Immunity 2: 167–175

Lethe B, Brasseur F and Boon T (1994) Human gene FHIT is a new gene encoding an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179: 921–930

Maggi A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP and Harris CC (1997) FHIT mutations in human primary gastric cancer. Cancer Res 57: 1435–1437

Morris B, Levy J, Barnea G, Cannizzaro LA, Li F, Nowell PC, Böel P, Wildmann C, Sensi ML, Brassieur R, Renaud JC, Coulié P, Boon T and Van der Bruggen P (1995) BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T-lymphocytes. Immunity 2: 167–175

Nickson J, Lord M and O’Fallon J (1997) Receptor protein-tyrosine kinase c-Src is a candidate tumour suppressor gene in human chromosome region 3p21. Proc Natl Acad Sci USA 88: 5036–5040

O’Fallon J (1997) The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin-A promoter. J Biol Chem 272: 30651–30661

© Cancer Research Campaign 1999

British Journal of Cancer (1999) 80(1/2), 73–78
Lima CD, Klein MG, Weinstein B and Hendrickson WA (1996) Three-dimensional structure of human protein kinase C interacting protein, a member of the HIT family of proteins. Proc Natl Acad Sci USA 93: 5357–5362

Momand J, Zametti GP, Olson DC, George D and Levine AJ (1992) The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245

Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K and Croce CM (1996) The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 56: 3173–3179

Ohnishi H, Kawanura M, Hanada R, Kaneko Y, Tsunoda Y, Hong T, Bessho F, Yokomori K and Hayashi Y (1996) Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastoma. Genes Chromosomes Cancer 15: 187–190

Ohba M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo I, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM and Huebner K (1996) The FHIT gene spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587–597

Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B (1992) Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 358: 80–83

Panagopoulos I, Thelin S, Mertens F, Mitelman F and Aman P (1997) Variable FHIT transcripts in non-neoplastic tissues. Genes Chromosom Cancer 19: 215–219

Russo V, Olerba P, Ricci A, Bonazzi C, Leone BE, Mangioni C, Allavena P, Bordignon C and Traversari C (1996) MAGE, BAGE and GAGE gene expression in fresh epithelial ovarian carcinomas. Int J Cancer 67: 457–460

Schlott T, Reimer S, Jahns A, Oldenbusch A, Rüschenburg I, Nagel H and Droese M (1997) Point mutations and nucleotide insertions in the MDM2 zinc-finger structure of human tumours. J Pathol 182: 54–61

Sigalas I, Calvert H, Anderson II, Neal DE and Lunec J (1996) Alternatively spliced MDM2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 2: 912–917

Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, DeGregorio L, Pastoreno U, Pierotti MA, Ohta M, Huebner K and Croce CM (1996) The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85: 17–26

Sozzi G, Sard L, DeGregorio L, Marchetti A, Musso K, Buttitta F, Tornielli S, Pellegrini S, Veronese ML, Manenti G, Incarbone M, Chella A, Angeletti CA, Pastoreno U, Huebner K, Bevilacqua G, Pilotti S, Croce CM and Pierotti MA (1997) Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57: 2121–2123

Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Willson JKV, Markowitz SD, Leach FS, Kinzler KW and Vogelstein B (1996) Evaluation of the FHIT gene in colorectal cancers. Cancer Res 56: 2936–2939

Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S and Boon T (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182: 689–698

Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B and Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647

Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K and Croce CM (1996) FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 93: 9770–9775

Wang N and Perkins KL (1984) Involvement of band 3p14 in t(3;8) hereditary renal carcinoma. Cancer Genet Cytogenet 11: 479–481

Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Ito K and Nishiy Y (1996) High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Heparatol 24: 1437–1440